234 related articles for article (PubMed ID: 37593242)
1. PD-L1 expression and prognosis in definitive radiotherapy patients with neuroendocrine cervical carcinoma.
Li H; Li X; Yang M; Su H; Zhang J; Hu C; Sun Y; Hu D; Chen L
J Clin Transl Res; 2023 Aug; 9(4):272-281. PubMed ID: 37593242
[TBL] [Abstract][Full Text] [Related]
2. Exploring a Better Adjuvant Treatment for Surgically Treated High-Grade Neuroendocrine Carcinoma of the Cervix.
Wang R; Xiao Y; Ma L; Wu Z; Xia H
Gynecol Obstet Invest; 2022; 87(6):398-405. PubMed ID: 36273460
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of PD-1 inhibitor combined with concurrent chemoradiotherapy in locally advanced cervical cancer with pelvic and/or para-aortic lymph node metastases: a retrospective cohort study.
Liu C; Ran X; Wang Z; Zhang K
Chin Clin Oncol; 2023 Aug; 12(4):38. PubMed ID: 37699603
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Chemotherapy in Locally Advanced Cervical Carcinoma - a Role in Patients with Para-aortic Lymph Node Involvement? A 10-year Institutional Experience.
Green HM; Counsell N; Ward A; McCormack M
Clin Oncol (R Coll Radiol); 2022 Jul; 34(7):e281-e290. PubMed ID: 35000828
[TBL] [Abstract][Full Text] [Related]
5. Comparison of salvage therapies for isolated para-aortic lymph node recurrence in patients with uterine cervical cancer after definitive treatment.
Kubota H; Tsujino K; Sulaiman NS; Sekii S; Matsumoto Y; Ota Y; Soejima T; Yamaguchi S; Sasaki R
Radiat Oncol; 2019 Dec; 14(1):236. PubMed ID: 31878944
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine carcinoma of the cervix: a systematic review of the literature.
Tempfer CB; Tischoff I; Dogan A; Hilal Z; Schultheis B; Kern P; Rezniczek GA
BMC Cancer; 2018 May; 18(1):530. PubMed ID: 29728073
[TBL] [Abstract][Full Text] [Related]
7. Definitive pelvic radiation therapy improves survival in stage IVB neuroendocrine cervical carcinoma: A NeCTuR study.
Salvo G; Jhingran A; Ramalingam P; Legarreta AF; Bhosale P; Gonzales NR; Chisholm GB; Frumovitz M
Gynecol Oncol; 2022 Jun; 165(3):530-537. PubMed ID: 35396134
[TBL] [Abstract][Full Text] [Related]
8. [Clinical analysis of 32 cases with neuroendocrine carcinoma of the uterine cervix in early-stage disease].
Wang Z; Wu L; Yao H; Sun Y; Li X; Li B; Zhang R; Ma S; Huang M
Zhonghua Fu Chan Ke Za Zhi; 2015 Mar; 50(3):198-203. PubMed ID: 26268410
[TBL] [Abstract][Full Text] [Related]
9. The clinicopathological features and treatment modalities associated with survival of neuroendocrine cervical carcinoma in a Chinese population.
Zhang X; Lv Z; Lou H
BMC Cancer; 2019 Jan; 19(1):22. PubMed ID: 30616631
[TBL] [Abstract][Full Text] [Related]
10. [Value of postoperative radiotherapy and analysis of prognostic factors in early-stage neuroendocrine carcinoma of cervix].
Song XC; Zhang H; Zhong S; Tan XJ; Ma SQ; Jin Y; Pan LY; Wu M; Cao DY; Yang JX; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2023 Sep; 58(9):680-690. PubMed ID: 37724385
[No Abstract] [Full Text] [Related]
11. Evaluation of the efficacy of prophylactic extended field irradiation in the concomitant chemoradiotherapy treatment of locally advanced cervical cancer, stage IIIB in the 2018 FIGO classification.
Meng Q; Liu X; Wang W; Hou X; Lian X; Sun S; Yan J; Liu Z; Miao Z; Hu K; Zhang F
Radiat Oncol; 2019 Dec; 14(1):228. PubMed ID: 31842919
[TBL] [Abstract][Full Text] [Related]
12. Extended-field radiotherapy for locally advanced cervical cancer.
Thamronganantasakul K; Supakalin N; Kietpeerakool C; Pattanittum P; Lumbiganon P
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012301. PubMed ID: 30362204
[TBL] [Abstract][Full Text] [Related]
13. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
[No Abstract] [Full Text] [Related]
14. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy.
Vrankar M; Stanic K
Radiol Oncol; 2018 Feb; 52(3):281-288. PubMed ID: 30210037
[TBL] [Abstract][Full Text] [Related]
15. [Outcomes and prognostic factors of advanced squamous cervical cancer after concurrent chemoradiotherapy].
Binbin T; Lingying W; Manni H; Jusheng A; Ning L
Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):348-54. PubMed ID: 25030731
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy after radiotherapy or concurrent chemoradiotherapy for pelvic lymph node-positive patients with locally advanced cervical cancer: a propensity score matching analysis.
Yuan Y; You J; Li X; Wang W
Int J Gynecol Cancer; 2022 Jan; 32(1):21-27. PubMed ID: 32474447
[TBL] [Abstract][Full Text] [Related]
17. Is Prophylactic Irradiation to Para-aortic Lymph Nodes in Locally Advanced Cervical Cancer Necessary?
Park SG; Kim JH; Oh YK; Byun SJ; Kim MY; Kwon SH; Kim OB
Cancer Res Treat; 2014 Oct; 46(4):374-82. PubMed ID: 25043821
[TBL] [Abstract][Full Text] [Related]
18. Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy.
Chen JL; Huang CY; Huang YS; Chen RJ; Wang CW; Chen YH; Cheng JC; Cheng AL; Kuo SH
Acta Obstet Gynecol Scand; 2014 Jul; 93(7):661-8. PubMed ID: 24666257
[TBL] [Abstract][Full Text] [Related]
19. Patterns of recurrence and survival in neuroendocrine cervical cancer.
Stecklein SR; Jhingran A; Burzawa J; Ramalingam P; Klopp AH; Eifel PJ; Frumovitz M
Gynecol Oncol; 2016 Dec; 143(3):552-557. PubMed ID: 27645621
[TBL] [Abstract][Full Text] [Related]
20. Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.
Liu J; Tang G; Zhou Q; Kuang W
Radiat Oncol; 2022 Aug; 17(1):142. PubMed ID: 35978412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
